Vir Biotechnology (VIR) As Gilead Deal Puts Its Valuation Narrative Back In Focus
Vir Biotechnology (VIR) has drawn fresh attention after signing a collaboration and license agreement with Gilead. The deal focuses on three PRO-XTEN dual-masked T-cell engager candidates aimed at selected solid tumor antigens.
Vir Biotechnology shares have had a strong run into this Gilead announcement, with a 90-day share price return of 20.11% and a year-to-date gain of 77.95%. The 1-year total shareholder return of 76.76% contrasts sharply with a 5-year total shareholder return that is down 71.99%.
Compare this Gilead tie-up with other oncology opportunities by scanning our hand-picked 34 healthcare AI stocks, using data-driven filters rather than headlines alone.
Vir Biotechnology now trades around the middle of a sharp gap between its recent price and published targets. After this Gilead rally, where does a reasonable view of fair value actually land for you?
Most Popular Narrative: 51% Undervalued
Against a last close of $10.57, the most followed narrative pegs Vir Biotechnology’s fair value at about $21.56, so the current quote sits well below that reference point and puts a lot of weight on how its hepatitis delta and oncology programs play out.
Vir Biotechnology's ECLIPSE Phase III program in hepatitis delta, which aims to become the new standard of care given the significant unmet medical need and regulatory designations, is expected to potentially drive revenue growth.
The strong foundational patent rights to the PRO-XTEN platform enable expansion into additional high-value oncology indications, potentially increasing earnings through diversification and broadening revenue streams.
See why 13 investors see Vir Biotechnology as 51% undervalued.
That storyline uses a 7.27% discount rate and assumes meaningful contribution from hepatitis delta therapies and PRO-XTEN based oncology candidates over time. This helps explain why the narrative fair value almost matches the current analyst consensus target of roughly $21.56 despite Vir Biotechnology remaining loss making and its revenue having declined 8.5% over the past year. The same view sits alongside a mixed quality profile, with a 2 out of 6 value score, forecast revenue contraction of 8.5% per year and expectations that earnings will continue to be in the red over the next three years, so any personal valuation work needs to weigh those risks against the upside implied by that 51% discount.
Result: Fair Value of $21.56 (UNDERVALUED)
Still, Vir Biotechnology’s reliance on unproven hepatitis delta and oncology programs, along with ongoing losses, means that clinical or regulatory setbacks could quickly rewrite that valuation story.
Find out about the key risks to this Vir Biotechnology narrative.
Another View: What Vir Biotechnology’s P/S Ratio Is Telling You
The fair value story around $21.56 leans on long term growth assumptions. On a simple P/S multiple, Vir Biotechnology trades at about 5.9x sales compared with 11.1x for the wider US biotech group and 22.8x for peers, yet the fair ratio for Vir is only 0.6x, which points to meaningful valuation risk if enthusiasm cools.
That gap between 5.9x and a 0.6x fair ratio reflects a market that is already baking in a lot of future success. The real question is how comfortable you are backing those hepatitis delta and oncology milestones before they fully play out.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around Vir Biotechnology feels finely balanced, it may be useful to quickly stress test the thesis against the underlying data. To see how those concerns stack up in context, start with these 3 important warning signs.
Looking for more investment ideas beyond Vir Biotechnology?
Vir Biotechnology may be front of mind after the Gilead news, but keeping fresh ideas on your radar is one way to avoid missing the next opportunity.
- Target potential mispricing by scanning a curated pool of quality candidates using the 29 high quality undervalued stocks.
- Prioritise resilience and capital protection by checking companies screened for sturdier financial footing through the 30 resilient stocks with low risk scores.
- Hunt for future leaders before the crowd catches on by reviewing the 21 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com